← Back to screener

CRESCENT BIOPHARMA, INC. CBIO

Rank #2525 · Nasdaq · $0.4B market cap
Audited by PricewaterhouseCoopers LLP, no going-concern flag in the latest filing.
Score
5.9
P/E
-2.4
P/B
–
ROE
–%
Op. Margin
-1407.5%
Debt Ratio
–%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -2.4x. Ranks in the top 94% of the universe.

Profitability ★☆☆☆☆
Poor

Profitability data unavailable.

Safety –
No data

Debt data unavailable.

Growth ★★★★★
Excellent

Revenue growth of 108340.0% year over year. Ranks in the top 0% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2014$0.0B$0.0B$0.0B$0.0B23.828
2015$0.0B$-0.0B$-0.0B$0.0B-265.752
2016$0.0B$-0.0B$-0.0B$0.0B-74.1275
2017$0.0B$-0.0B$-0.0B$0.1B-63.714
2018$0.0B$-0.0B$-0.0B$0.0B-172505.322
2019–$-0.0B$-0.0B$0.0B–27
2020$0.0B$-0.1B$-0.0B$0.1B-506.812
2021$0.0B$-0.1B$-0.1B$0.2B-604.17
2022$0.0B$-0.1B$-0.1B$0.2B-506.88
2023$0.0B$-0.1B$-0.1B$0.1B-5470.77
2024$0.0B$-0.0B$-0.0B$0.0B-392752.916
2025$0.0B$-0.2B$-0.2B$0.0B-1407.5–

← See the full screener